Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) CEO David Domzalski sold 5,096 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $3.75, for a total transaction of $19,110.00. Following the completion of the transaction, the chief executive officer now owns 214,595 shares in the company, valued at $804,731.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ:FOMX opened at $3.22 on Friday. Foamix Pharmaceuticals Ltd has a one year low of $3.13 and a one year high of $7.60. The firm has a market capitalization of $173.99 million, a PE ratio of -1.89 and a beta of 1.70.
Institutional investors and hedge funds have recently made changes to their positions in the business. Federated Investors Inc. PA purchased a new stake in Foamix Pharmaceuticals during the 3rd quarter valued at $287,000. ETF Managers Group LLC lifted its position in shares of Foamix Pharmaceuticals by 66.6% in the 4th quarter. ETF Managers Group LLC now owns 81,972 shares of the specialty pharmaceutical company’s stock worth $294,000 after purchasing an additional 32,773 shares during the period. Eversept Partners LP lifted its position in shares of Foamix Pharmaceuticals by 7.7% in the 4th quarter. Eversept Partners LP now owns 294,660 shares of the specialty pharmaceutical company’s stock worth $1,058,000 after purchasing an additional 21,093 shares during the period. Stonepine Capital Management LLC lifted its position in shares of Foamix Pharmaceuticals by 134.7% in the 4th quarter. Stonepine Capital Management LLC now owns 1,293,177 shares of the specialty pharmaceutical company’s stock worth $4,643,000 after purchasing an additional 742,099 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Foamix Pharmaceuticals in the 3rd quarter worth about $6,616,000. 59.61% of the stock is owned by institutional investors and hedge funds.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Featured Article: Municipal Bonds
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.